Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study

Published:2021-09-18 Issue:11 Volume:12 Page:2907-2920
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Kim Hae Jin,Kim Young Sik,Lee Chang Beom,Choi Moon-Gi,Chang Hyuk-Jae,Kim Soo Kyoung,Yu Jae Myung,Kim Tae Ho,Lee Ji Hyun,Ahn Kyu Jeung,Min Kyung Wan,Kyung Eun Jung,Kim Yeo Kyeong,Lee Kwan Woo^ORCID

Funder

handok inc., seoul, republic of korea

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13300-021-01148-1.pdf

Reference32 articles.

1. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.

2. Ha KH, Kim DJ. Current status of managing diabetes mellitus in Korea. Korean J Intern Med. 2016;31:845–50.

3. Jung CH, Son JW, Kang S, et al. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J. 2021;45:1–10.

4. Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013;6:187–95.

5. Nakamura Y, Hasegawa H, Tsuji M, et al. Diabetes therapies in hemodialysis patients: dipeptidase-4 inhibitors. World J Diabetes. 2015;6:840–9.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study;Expert Review of Endocrinology & Metabolism;2023-05-26

2. Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects;Expert Review of Clinical Pharmacology;2023-01-02

3. Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study;Diabetes Therapy;2022-11-23